ANALYTICAL AND LABORATORY EQUIPMENT 7
have the right people and systems in place to make this happen”.
Renishaw Diagnostics, formerly D3 Technologies, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.
Renishaw Diagnostics has launched its first RenDx research-use-only (RUO) multiplex assay system and is working towards the obtaining of CE marking for the system as an in vitro medical device in Europe and clearance in the US.
One major challenge in studying
epigenetic enzymes and their corresponding modifications is their existence in multiprotein complexes and the complexes’ impact on their activity. So the ability to study these enzymes and to identify compounds that translate into useful drugs in vivo is greatly facilitated by the ability to incorporate cell-based assays using therapeutically relevant cell backgrounds.
Te BacMam Histone H3 cellular assay kits from Life Technologies allow users to choose the modifications that correspond to the enzymes of interest in the chosen cell background or multiple cell background.
Te BacMam reagent is used to transduce cells and drives expression of GFP-Histone H3 fusion protein in the cell background of interest. Te GFP-Histone H3 is now a substrate for a variety of epigenetic enzymes such as methyltransferases. In the presence of a terbium (Tb)-labelled modification- specific antibody (such as anti
histone H3K4me2), the binding of the antibody to the Histone H3 substrate results in time-resolved fluorescence resonance energy transfer (TR-FRET) between the GFP and the Tb.
Monitoring the TR-FRET readout in the presence of cells treated with compounds enables the identification of inhibitors of epigenetic enzymes for that particular modification.
EMD Millipore’s new Millicell µ-Migration assay kit is a slide- based platform that can be used to visualise and measure the effects of chemo-attractants on the migration of adherent cells in real time. Te kit is useful for studying metastatic behaviour or the effects of toxins.
Te Millicell µ-Migration assay replaces the filter used in traditional Boyden chambers with microchannels. Cells migrating in these channels can be directly observed and their progress can be quantitatively measured. Te
kit also provides a stable linear concentration gradient for up to 48 hours. With high optical properties similar to those of glass, the Millicell µ-Migration slide is suitable for the analysis of slow- or fast-moving cells by video microscopy. Up to three assays can be run in parallel on each slide with approximately 100 to 200 cells per assay. Te kit comes assembled and ready to use with a Millicell µ-Migration slide and migration assay reagents.
Finally, Lonza’s new NodeSensor assays are based on the protein- fragment complementation principle, and they enable visualisation of protein complex dynamics within living human cells. NodeSensor assays can directly measure the activity of undruggable targets such as transcription factors and proteasome components, as well as mainstream drug targets (such as GPCRs) within their natural cellular context. When combining different NodeSensor assays with high- content analysis, a range of cellular responses becomes visible.
Circle 7 or ✔ at
www.scientistlive.com/eurolab
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52